Ultragenyx reviews apazunersen and plans cost cuts after Phase 3 miss
Ultragenyx said it will reduce expenses and evaluate its development of apazunersen after the drug failed to meet its primary endpoint in a Phase 3 trial, which targeted improved cognitive scores in Angelman syndrome patients.
Ultragenyx Pharmaceutical said it will look to reduce expenses and review its development of apazunersen after the drug failed to meet its primary endpoint in a Phase 3 trial. The treatment did not meet the primary endpoint of improving cognitive scores in patients with Angelman syndrome.